Literature DB >> 26990531

CXCR5 is critically involved in progression of lupus through regulation of B cell and double-negative T cell trafficking.

A Wiener1, A Schippers1, N Wagner1, F Tacke2, T Ostendorf3, N Honke1, K Tenbrock, K Ohl1.   

Abstract

The recruitment of immune cells to sites of tissue inflammation is orchestrated by chemokine/chemokine receptor networks. Among these, the CXCL13/CXCR5 axis is thought to be involved critically in systemic lupus erythematosus (SLE) and lupus nephritis pathogenesis. Beyond B cell abnormalities, another hallmark of SLE disease is the occurrence of aberrant T cell responses. In particular, double-negative (DN) T cells are expanded in the peripheral blood of patients with SLE and in lupus-prone mice. DN T cells induce immunoglobulin production, secrete proinflammatory cytokines and infiltrate inflamed tissue, including kidneys. We aimed to investigate how CXCR5 deficiency changes immune cell trafficking in murine lupus. We therefore crossed CXCR5(-/-) mice with B6/lpr mice, a well-established murine lupus model. B cell numbers and B cellular immune responses were diminished in CXCR5-deficient B6/lpr mice. In addition, we observed reduced accumulation of DN T cells in spleen and lymph nodes, paralleled by reduced splenomegaly and lymphadenopathy. In-vivo migration assays revealed reduced migration of CXCR5-deficient DN T cells into lymph nodes, and ex-vivo-activated CXCR5-deficient DN T cells failed to infiltrate kidneys of recipients. Moreover, DN T cells and B cells of CXCR5-deficient B6/lpr mice failed to migrate towards CXCL13 in vitro. We propose that CXCR5 is involved critically in B cell trafficking and germinal cell (GC) formation in murine lupus and in guiding pathogenic DN T cells into lymphoid organs and kidneys, and we therefore describe new pathomechanisms for the CXCL13/CXCR5 axis in SLE.
© 2016 British Society for Immunology.

Entities:  

Keywords:  CXCR5; DN T cells; SLE

Mesh:

Substances:

Year:  2016        PMID: 26990531      PMCID: PMC4908294          DOI: 10.1111/cei.12791

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  31 in total

1.  Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression.

Authors:  Z X Zhang; L Yang; K J Young; B DuTemple; L Zhang
Journal:  Nat Med       Date:  2000-07       Impact factor: 53.440

Review 2.  Systemic lupus erythematosus.

Authors:  George C Tsokos
Journal:  N Engl J Med       Date:  2011-12-01       Impact factor: 91.245

Review 3.  Double negative regulatory T cells in transplantation and autoimmunity: recent progress and future directions.

Authors:  Stephen C Juvet; Li Zhang
Journal:  J Mol Cell Biol       Date:  2012-02       Impact factor: 6.216

4.  Interleukin-2 treatment reverses effects of cAMP-responsive element modulator α-over-expressing T cells in autoimmune-prone mice.

Authors:  K Ohl; A Wiener; A Schippers; N Wagner; K Tenbrock
Journal:  Clin Exp Immunol       Date:  2015-05-14       Impact factor: 4.330

Review 5.  B-cell depletion in the treatment of lupus nephritis.

Authors:  Jon W Gregersen; David R W Jayne
Journal:  Nat Rev Nephrol       Date:  2012-07-17       Impact factor: 28.314

6.  Increased serum levels of soluble L-selectin (CD62L) in patients with active systemic lupus erythematosus (SLE).

Authors:  J Font; P Pizcueta; M Ramos-Casals; R Cervera; M García-Carrasco; M Navarro; M Ingelmo; P Engel
Journal:  Clin Exp Immunol       Date:  2000-01       Impact factor: 4.330

7.  The role of IL-23/IL-17 axis in lupus nephritis.

Authors:  Zheng Zhang; Vasileios C Kyttaris; George C Tsokos
Journal:  J Immunol       Date:  2009-08-05       Impact factor: 5.422

8.  Pathogenetic role of glomerular CXCL13 expression in lupus nephritis.

Authors:  K Worthmann; F Gueler; S von Vietinghoff; A Davalos-Mißlitz; F Wiehler; A Davidson; T Witte; H Haller; M Schiffer; C S Falk; L Schiffer
Journal:  Clin Exp Immunol       Date:  2014-10       Impact factor: 4.330

9.  T cell receptor alpha/beta expressing double-negative (CD4-/CD8-) and CD4+ T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis.

Authors:  S Shivakumar; G C Tsokos; S K Datta
Journal:  J Immunol       Date:  1989-07-01       Impact factor: 5.422

10.  Inhibition of aberrant circulating Tfh cell proportions by corticosteroids in patients with systemic lupus erythematosus.

Authors:  Xuebing Feng; Dandan Wang; Jingjing Chen; Lin Lu; Bingzhu Hua; Xia Li; Betty P Tsao; Lingyun Sun
Journal:  PLoS One       Date:  2012-12-17       Impact factor: 3.240

View more
  13 in total

1.  Neutrophil-to-C3 ratio and neutrophil-to-lymphocyte ratio were associated with disease activity in patients with systemic lupus erythematosus.

Authors:  Jianlin Yu; Tingting Zeng; Yang Wu; Yongjian Tian; Liming Tan; Xinwang Duan; Qiong Wu; Hua Li; Le Yu
Journal:  J Clin Lab Anal       Date:  2018-08-20       Impact factor: 2.352

Review 2.  Research and therapeutics-traditional and emerging therapies in systemic lupus erythematosus.

Authors:  Laurie S Davis; Andreas M Reimold
Journal:  Rheumatology (Oxford)       Date:  2017-04-01       Impact factor: 7.580

Review 3.  TCRαβ+ CD4-/CD8- "double negative" T cells in health and disease-implications for the kidney.

Authors:  Andrea M Newman-Rivera; Johanna T Kurzhagen; Hamid Rabb
Journal:  Kidney Int       Date:  2022-04-09       Impact factor: 18.998

Review 4.  Chemokines and Chemokine Receptors in the Development of Lupus Nephritis.

Authors:  Xiaofeng Liao; Tharshikha Pirapakaran; Xin M Luo
Journal:  Mediators Inflamm       Date:  2016-06-14       Impact factor: 4.711

5.  The correlational research among serum CXCL13 levels, circulating plasmablasts and memory B cells in patients with systemic lupus erythematosus: A STROBE-compliant article.

Authors:  Chenglong Fang; Tingting Luo; Ling Lin
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

6.  CD11c-Specific Deletion Reveals CREB as a Critical Regulator of DC Function during the Germinal Center Response.

Authors:  Kim Ohl; Anastasia Schippers; Klaus Tenbrock
Journal:  J Immunol Res       Date:  2018-05-07       Impact factor: 4.818

7.  Stabilized β-Catenin Ameliorates ALPS-Like Symptoms of B6/lpr Mice.

Authors:  Xiaoxie Xu; Jun Huang; Mei Zhao; Huanpeng Chen; Jinhua Mo; Xiaoqing Zhou; Qiao Su; Bolan Yu; Zhaofeng Huang
Journal:  J Immunol Res       Date:  2017-11-09       Impact factor: 4.818

8.  A highly potent lymphatic system-targeting nanoparticle cyclosporine prevents glomerulonephritis in mouse model of lupus.

Authors:  Raghu Ganugula; Meenakshi Arora; Dianxiong Zou; Sandeep K Agarwal; Chandra Mohan; M N V Ravi Kumar
Journal:  Sci Adv       Date:  2020-06-12       Impact factor: 14.136

Review 9.  The Role of CXCL13 in Antibody Responses to HIV-1 Infection and Vaccination.

Authors:  Yonas Bekele Feyissa; Francesca Chiodi; Yongjun Sui; Jay A Berzofsky
Journal:  Front Immunol       Date:  2021-02-25       Impact factor: 7.561

Review 10.  A Comprehensive Review of Biological Agents for Lupus: Beyond Single Target.

Authors:  Bingyi Yang; Ming Zhao; Haijing Wu; Qianjin Lu
Journal:  Front Immunol       Date:  2020-10-02       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.